NSCLC market seen reaching $36.9 billion by 2031

Allied Market Research says the global non-small-cell lung cancer market was worth $15.3 billion in 2021 and is projected to hit $36.9 billion by 2031, driven by a 9.3% CAGR. The report points to rising lung cancer prevalence, especially among smokers and tobacco users, while high treatment costs and regulatory hurdles may slow growth.

Why it matters: - The non-small-cell lung cancer market is expanding as demand rises for therapies that address one of the most common forms of lung cancer. - The market’s projected growth signals opportunity for drug developers, investors, and healthcare distributors across treatment, pharmacy, and regional channels.

What happened: - Allied Market Research released a report on the global non-small-cell lung cancer market covering type, treatment type, distribution channel, and regional outlook. - The report values the market at $15.3 billion in 2021 and projects it will reach $36.9 billion by 2031. - The forecast calls for a 9.3% CAGR from 2022 to 2031. - The report was published in Portland, Oregon. - The company made the full study available through a sample PDF report. - The company also offered purchase information.

The details: - The report segments the market by adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others. - The report segments treatment into chemotherapy, targeted therapy, and immunotherapy. - The report tracks hospital pharmacy, drug store and retail pharmacy, and online pharmacy channels. - Adenocarcinoma held nearly half the market in 2021 and is expected to keep its lead through 2031. - Large cell carcinoma is projected to post the fastest growth in the type segment, with a 11.3% CAGR from 2022 to 2031. - Targeted therapy held more than half the market in 2021 and is expected to remain the largest treatment segment. - Immunotherapy is projected to grow the fastest among treatments, at a 12.7% CAGR from 2022 to 2031. - Hospital pharmacy accounted for more than two-thirds of the market in 2021 and is expected to stay in front. - Online pharmacy is expected to record the fastest channel growth, with a 15.1% CAGR from 2022 to 2031. - North America held about two-fifths of global revenue in 2021 and is expected to remain the largest regional market. - Asia-Pacific is projected to be the fastest-growing region, with a 10.5% CAGR from 2022 to 2031. - The report names F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Celgene Corporation, Sanofi, and Boehringer Ingelheim among the top companies. - The regional outlook in the report includes North America, Europe, Asia-Pacific, and LAMEA.

Between the lines: - Smoking and tobacco use remain central demand drivers for NSCLC treatment spending. - High treatment costs and strict government approval rules are cited as restraints on market growth. - The strong outlook for targeted therapy and immunotherapy suggests continued investment in more precise and higher-value cancer treatments. - Online pharmacy growth points to a broader shift in how oncology drugs may be distributed and accessed.

What’s next: - The report expects the market to keep expanding through 2031 as diagnosis and treatment demand rises. - Market players are likely to keep investing in product development, especially in immunotherapy and other advanced therapies. - Regional competition is expected to intensify as Asia-Pacific attracts more public and private investment.

The bottom line: - NSCLC remains a large and growing oncology market, with the fastest growth centered on advanced therapies, digital pharmacy channels, and Asia-Pacific expansion.